Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06788912
What this trial is testing

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

Who this might be right for
Lung Neoplasm Malignant
Merck Sharp & Dohme LLC 60
Large-scale testing (Phase 3)Study completedNCT02358031
What this trial is testing

Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)

Who this might be right for
Recurrent Head and Neck CancerMetastatic Head and Neck Cancer
Merck Sharp & Dohme LLC 882
Large-scale testing (Phase 3)Study completedNCT02702401
What this trial is testing

Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)

Who this might be right for
Hepatocellular Carcinoma
Merck Sharp & Dohme LLC 413
Testing effectiveness (Phase 2)Active Not RecruitingNCT06483334
What this trial is testing

Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

Who this might be right for
Metastatic Urothelial CarcinomaLocally Advanced Urothelial Carcinoma
Merck Sharp & Dohme LLC 38
Testing effectiveness (Phase 2)Study completedNCT03631784
What this trial is testing

A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)

Who this might be right for
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 216
Large-scale testing (Phase 3)Study completedNCT03062358
What this trial is testing

Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)

Who this might be right for
Carcinoma, Hepatocellular
Merck Sharp & Dohme LLC 453
Large-scale testing (Phase 3)Ended earlyNCT03924869
What this trial is testing

Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

Who this might be right for
Non-Small Cell Lung Cancer
Merck Sharp & Dohme LLC 448
Early research (Phase 1)Study completedNCT06460961
What this trial is testing

MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)

Who this might be right for
Neoplasm Metastasis
Merck Sharp & Dohme LLC 40
Large-scale testing (Phase 3)Active Not RecruitingNCT02362594
What this trial is testing

Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)

Who this might be right for
Melanoma
Merck Sharp & Dohme LLC 1,019
Large-scale testing (Phase 3)Study completedNCT05600309
What this trial is testing

Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

Who this might be right for
Colorectal Cancer
Merck Sharp & Dohme LLC 94
Large-scale testing (Phase 3)Study completedNCT03189719
What this trial is testing

First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)

Who this might be right for
Esophageal Neoplasms
Merck Sharp & Dohme LLC 749
Testing effectiveness (Phase 2)Looking for participantsNCT06445972
What this trial is testing

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

Who this might be right for
Gastroesophageal JunctionGastroesophageal AdenocarcinomaEsophageal Neoplasms+1 more
Merck Sharp & Dohme LLC 210
Testing effectiveness (Phase 2)Ended earlyNCT03598608
What this trial is testing

Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)

Who this might be right for
Hodgkin DiseaseLymphoma, Non-HodgkinLymphoma, B-Cell
Merck Sharp & Dohme LLC 137
Large-scale testing (Phase 3)Looking for participantsNCT06170788
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC 614
Testing effectiveness (Phase 2)Active Not RecruitingNCT06305767
What this trial is testing

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

Who this might be right for
Bladder Cancer
Merck Sharp & Dohme LLC 230
Large-scale testing (Phase 3)Study completedNCT03834519
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)

Who this might be right for
Prostatic Neoplasms
Merck Sharp & Dohme LLC 793
Early research (Phase 1)Study completedNCT02054806
What this trial is testing

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)

Who this might be right for
Solid Tumor
Merck Sharp & Dohme LLC 477
Large-scale testing (Phase 3)Study completedNCT05064059
What this trial is testing

Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

Who this might be right for
Colorectal Cancer
Merck Sharp & Dohme LLC 441
Large-scale testing (Phase 3)Study completedNCT02494583
What this trial is testing

Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)

Who this might be right for
Gastric Adenocarcinoma
Merck Sharp & Dohme LLC 763
Large-scale testing (Phase 3)Study completedNCT03829319
What this trial is testing

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

Who this might be right for
Nonsquamous Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 761
Next Page